Tag: relief

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025, all dates inclusive (the “Class Period”), have until July 21, 2025 to seek appointment as lead plaintiff of the DoubleVerify class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. DoubleVerify Holdings, Inc., No. 25-cv-04332 (S.D.N.Y.), the DoubleVerify class action lawsuit charges DoubleVerify as well as certain of DoubleVerify’s top executives with violations of the Securities Exchange Act of 1934.

Facilities and care team tailored for patients with complex medical needs

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc., No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat and certain of Red Cat’s top current and former executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ibotta, Inc. (NYSE: IBTA) publicly traded securities pursuant and/or traceable to Ibotta’s registration statement and related prospectus issued in connection with Ibotta’s initial public offering (the “IPO”) held on or around April 18, 2024, have until Monday, June 16, 2025 to seek appointment as lead plaintiff of the Ibotta class action lawsuit. Captioned Fortune v. Ibotta, Inc., No. 25-cv-01213 (D. Colo.), the Ibotta class action lawsuit charges Ibotta as well as certain of Ibotta’s top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933.

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma’s top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933.